Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort.

clinical epidemiology connective tissue disease interstitial lung disease pulmonary hypertension rare lung disease

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
21 Oct 2021
Historique:
received: 24 09 2021
revised: 18 10 2021
accepted: 19 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 14 11 2021
Statut: epublish

Résumé

Interstitial lung disease (ILD) is associated with impaired survival among patients with connective tissue diseases (CTDs), but population-based data on the frequency of ILD and pulmonary hypertension (PH) in different CTD subtypes and the impact on survival are sparse. We included patients with a first-time ICD-10 diagnosis of systemic sclerosis (SSc), mixed connective tissue disease (MCTD), myositis, systemic lupus erythematosus (SLE), or Sjögren's disease registered in the Danish National Patient Registry between 2000 and 2015. Among these, we identified patients with ILD and PH. Using Kaplan-Meier analysis, we assessed survival for the five subtypes of CTD ± ILD and compared survival among CTD patients overall ± ILD with survival in the general population ± ILD. We identified 11,731 patients with a diagnosis of CTD; 637 (5.4%) had a diagnosis of ILD. The proportion of patients with ILD was higher in SSc (13.4%) and MCTD (9.1%) than in myositis (6.0%), SLE (4.1%), and Sjögren (2.8%). Fifty-one percent were diagnosed with ILD in their fifties and sixties. PH was more frequent in SSc (7.5%) and MCTD (4.1%). Five-year survival was 73.3% (66.7-80.6) in SSc-ILD, 81.0% (69.0-95.1) in MCTD-ILD, 84.7% (77.3-92.9) in myositis-ILD, 83.5% (76.2-91.5) in SLE-ILD, and 84.7 (78.4-91.6) in Sjögren-associated ILD. Survival in CTD-ILD overall was impaired for all age groups compared with CTD alone. Age-stratified survival was comparable between CTD-ILD and ILD in the general population. The survival gap between ILD and non-ILD increased with age. Survival was comparable between different CTD-ILD subtypes and comparable to survival in non-CTD-ILD.

Identifiants

pubmed: 34768349
pii: jcm10214830
doi: 10.3390/jcm10214830
pmc: PMC8584507
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Skibsreder Per Henriksen & Hustru's Fond.
ID : No specific number
Organisme : Gigtforeningen
ID : R160-A5098

Références

Rheumatology (Oxford). 2013 Jul;52(7):1208-13
pubmed: 23407386
Clin Rheumatol. 2009 Jun;28(6):639-46
pubmed: 19247576
Rheumatology (Oxford). 2020 Oct 1;59(10):2920-2929
pubmed: 32097470
BMC Rheumatol. 2018 Dec 7;2:36
pubmed: 30886986
Rheumatology (Oxford). 2018 Feb 1;57(2):255-262
pubmed: 28379478
Arthritis Res Ther. 2018 Jan 30;20(1):17
pubmed: 29382380
Lancet Respir Med. 2020 May;8(5):453-460
pubmed: 32145830
Clin Rheumatol. 1998;17(6):468-77
pubmed: 9890674
Scand J Gastroenterol. 2020 Oct;55(10):1171-1175
pubmed: 32838593
Arthritis Res Ther. 2019 Feb 6;21(1):48
pubmed: 30728079
Ann Am Thorac Soc. 2018 Dec;15(12):1427-1433
pubmed: 30188737
Arthritis Rheumatol. 2017 May;69(5):1067-1077
pubmed: 28029745
BMJ. 2016 Feb 24;352:h6819
pubmed: 26912511
Ann Rheum Dis. 2017 Oct;76(10):1700-1706
pubmed: 28611082
Lancet Respir Med. 2016 Sep;4(9):708-719
pubmed: 27469583
Ann Rheum Dis. 2009 Jun;68(6):961-5
pubmed: 18511546
Arthritis Rheumatol. 2019 Aug;71(8):1339-1349
pubmed: 30762947
Clin Epidemiol. 2017 Nov 29;9:627-632
pubmed: 29238225
Lupus. 2012 Nov;21(13):1412-22
pubmed: 22864236
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1258-1266
pubmed: 31310156
Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6
pubmed: 12070056
Lupus. 2016 Aug;25(9):1004-11
pubmed: 26846692
Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631
pubmed: 29868924
Ann Rheum Dis. 2021 Feb;80(2):219-227
pubmed: 32988845
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Lung. 2016 Oct;194(5):733-7
pubmed: 27166633
Arthritis Care Res (Hoboken). 2016 Dec;68(12):1843-1848
pubmed: 26946215
Arthritis Res Ther. 2018 Dec 19;20(1):280
pubmed: 30567600
Medicine (Baltimore). 2008 Jul;87(4):210-219
pubmed: 18626304
BMJ Open. 2016 Nov 18;6(11):e012832
pubmed: 27864249
Ann Rheum Dis. 2018 Jan;77(1):30-39
pubmed: 28855174
Chest. 2017 Nov;152(5):999-1007
pubmed: 28629914
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Rheumatology (Oxford). 2013 Jan;52(1):173-9
pubmed: 23192906

Auteurs

Charlotte Hyldgaard (C)

Diagnostic Centre, Silkeborg Regional Hospital, University Clinic for Innovative Patient Pathways, Aarhus University, 8600 Silkeborg, Denmark.

Elisabeth Bendstrup (E)

Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200 Aarhus, Denmark.

Alma Becic Pedersen (AB)

Department of Clinical Epidemiology, Aarhus University Hospital, 8200 Aarhus, Denmark.

Lars Pedersen (L)

Department of Clinical Epidemiology, Aarhus University Hospital, 8200 Aarhus, Denmark.

Torkell Ellingsen (T)

Diagnostic Centre, Silkeborg Regional Hospital, University Clinic for Innovative Patient Pathways, Aarhus University, 8600 Silkeborg, Denmark.
Rheumatology Research Unit, Odense University Hospital, University of Southern Denmark, 5000 Odense, Denmark.

Classifications MeSH